Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2026)

Neurocrine Biosciences (NBIX) has reported Cost of Revenue for 10 consecutive years, with $23.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 125.24% year-over-year to $23.2 million; the trailing twelve-month figure through Jun 2026 stood at $68.6 million (up 86.41% YoY), and the FY2025 full-year result was $52.1 million, up 53.24% from the prior year.
• Cost of Revenue improved to $23.2 million in Q2 2026 per NBIX's latest filing, from $13.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $23.2 million in Q2 2026 and bottomed at $4.6 million in Q1 2022.
• Historically, Cost of Revenue has averaged $10.3 million across 5 years, with a median of $9.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue jumped 139.58% in 2023, then declined 28.57% in 2024.
• Over 5 years, Cost of Revenue stood at $7.7 million in 2022, then gained by 10.39% to $8.5 million in 2023, then advanced by 9.41% to $9.3 million in 2024, then soared by 89.25% to $17.6 million in 2025, then surged by 31.82% to $23.2 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $23.2 million, $13.8 million, and $17.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.